ArticleJournal of pain research2026
Transcranial Direct Current Stimulation Targeting the Primary Motor Cortex Suppresses Activity in the Ventrolateral Periaqueductal Gray and Alleviates Chronic Pain in a Rat Model of Knee Osteoarthritis.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Transcranial direct current stimulation (tDCS) shows promise for chronic pain treatment; however, its efficacy and mechanisms in knee osteoarthritis (KOA)-associated pain remain unclear. This study aimed to evaluate the analgesic effects of primary motor cortex (M1)-targeted tDCS in a rat model of KOA and to investigate the underlying mechanisms. Methods: A chronic KOA model was established via unilateral intra-articular monoiodoacetate (MIA) injection. Mechanical allodynia and thermal hyperalgesia were assessed using von Frey filaments and a hot plate test. Neuronal activation and microglial responses in the ventrolateral periaqueductal gray (vlPAG) were evaluated by immunohistochemistry, and inflammatory cytokines were quantified using qPCR. The effects of M1-targeted tDCS on vlPAGactivity, microglial activation, and pain behaviors were examined. Minocycline was administered into the vlPAG to inhibit microglial. CTB-555 retrograde tracing was used to map M1-vlPAG connectivity. Results: MIA induced persistent pain hypersensitivity, accompanied by increased neuronal activity, microglial activation, and elevated pro-inflammatory cytokines in the contralateral vlPAG. Local administration of minocycline suppressed both microglial and neuronal activation and alleviated pain behaviors. M1-targeted tDCS significantly reduced pain hypersensitivity, suppressed vlPAG neuronal activity and microglial activation, and downregulated inflammatory cytokines expression. Conclusion: KOA-associated chronic pain is linked to increased neuronal activity and neuroinflammation in the vIPAG. M1-targeted tDCS alleviates pain, likely by suppressing vIPAG activity and microglial-mediated inflammation via the M1-vlPAG pathway. However, given differences between the MIA model and human osteoarthritis, caution is required in clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.